We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Red Blood Cell Transfusion Benefits Analyzed for Trauma Patients

By LabMedica International staff writers
Posted on 02 Jul 2014
Print article
Image: Red blood cell transfusion pack (Photo courtesy of Australian Red Cross).
Image: Red blood cell transfusion pack (Photo courtesy of Australian Red Cross).
The risks and benefits of red blood cell transfusions for patients with trauma and major bleeding might vary considerably based on a patient's predicted risk of death on arrival at a trauma center.

Trauma patients who have the highest predicted risk of death on arrival at a trauma center receive the greatest benefit from red blood cell transfusions, but for those with the lowest predicted risk of death at baseline red blood cell transfusion is associated with a higher chance of death.

Scientists at the London School of Hygiene and Tropical Medicine (UK) evaluated the association between receiving red blood cell (RBC) transfusion versus not receiving a RBC transfusion with deaths by all causes at 28 days post-trauma. The findings were stratified by predicted risk of death based on clinical observations on arrival at the trauma center. The investigators included 20,127 trauma patients with significant bleeding from 274 hospitals in 40 countries in their study.

The authors found that those at greatest predicted risk of dying, greater than 50%, had a smaller chance of death from all causes if they were transfused, while for those in the 21% to 50% risk group there was no significant difference in their chance of dying based on whether they are transfused or not. Patients at a 6% to 10% chance of death had a high odd ratio (OR) of 2.31 for dying if they received a transfusion, while for those whose initial risk was below 6%, the OR for death associated with transfusion was very high at 5.40. RBC transfusion was associated with 5.1 more deaths per 100 patients in the patient group with the lowest predicted risk of death but with 11.9 fewer deaths per 100 patients in the group with the highest predicted risk of death.

The authors concluded that although RBC transfusion might be life-saving for patients with hemorrhagic shock, uncertainty remains about the best early transfusion strategy in other patients. Their study suggests that blood transfusion could be harmful for those patients whose predicted risk of death is low. However, as the study was observational, important biases cannot be ruled out, and they do not claim a causal link.

Druin Burch, MD, a consulting editor of the journal, said, “With so many dying each year, and with deaths from injury set to rise in importance as road traffic crashes and violent injuries account for a greater portion of the global burden of disease, we have a compelling reason to improve and rationalize our transfusion strategies.” The study was published on June 17, 2014, in the journal Public Library of Science Medicine.

Related Links:

London School of Hygiene and Tropical Medicine


Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.